公开(公告)号：EP1465638B1

公开(公告)日：2007-05-16

申请号：EP02806234.7

申请日：2002-12-24

申请人： GENZYME CORPORATION

发明人： JOZEFIAK, Thomas, H. ,  BASTOS, Cecilia, M. ,  PAPOULIS, Andrew, T. ,  HOLMES-FARLEY, Stephen, Randall

IPC分类号： A61K31/18 ,  A61P13/12 ,  A61P19/10 ,  A61P3/14

CPC分类号： A61K45/06 ,  A61K31/166 ,  A61K31/17 ,  A61K31/18 ,  A61K31/415 ,  A61K31/63 ,  A61K33/38 ,  A61K2300/00

摘要： Disclosed are compounds, which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar1-W-X-Y-Ar2; or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C 1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.

公开(公告)号：EP2349255B1

公开(公告)日：2016-03-30

申请号：EP09741487.4

申请日：2009-10-02

申请人： Genzyme Corporation

发明人： SIEGEL, Craig ,  BASTOS, Cecilia, M. ,  HARRIS, David, J. ,  DIOS, Angeles ,  LEE, Edward ,  SILVA, Richard ,  CUFF, Lisa, M. ,  LEVINE, Mikaela ,  CELATKA, Cassandra, A. ,  JOZEFIAK, Thomas, H. ,  VINICK, Frederic ,  XIANG, Yibin ,  KANE, John ,  LIAO, Junkai

IPC分类号： A61K31/4025 ,  C07C271/12 ,  C07D207/10 ,  C07D295/04 ,  C07D295/10 ,  C07D319/08 ,  C07D405/06 ,  C07D405/14 ,  C07D407/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/14

CPC分类号： A61K31/4025 ,  C07C271/12 ,  C07D207/12 ,  C07D317/60 ,  C07D319/18 ,  C07D319/20 ,  C07D333/16 ,  C07D407/06 ,  C07D407/12 ,  C07D409/04 ,  C07D413/04 ,  C07D417/12

公开(公告)号：EP1465638A2

公开(公告)日：2004-10-13

申请号：EP02806234.7

申请日：2002-12-24

申请人： GENZYME CORPORATION

发明人： JOZEFIAK, Thomas, H. ,  BASTOS, Cecilia, M. ,  PAPOULIS, Andrew, T. ,  HOLMES-FARLEY, Stephen, Randall

IPC分类号： A61K31/63 ,  A61K31/166 ,  A61K31/415 ,  A61K31/17 ,  A61P13/12 ,  A61P19/10 ,  A61P3/14

CPC分类号： A61K45/06 ,  A61K31/166 ,  A61K31/17 ,  A61K31/18 ,  A61K31/415 ,  A61K31/63 ,  A61K33/38 ,  A61K2300/00

摘要： Disclosed are compounds, which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar1-W-X-Y-Ar2; or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C 1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function. The methods comprise the step of administering an effective amount of the one of the compounds described above.

摘要翻译： 公开了已被鉴定为磷酸盐转运抑制剂的化合物。 许多化合物由结构式（I）表示：Ar 1 -W-X-Y-Ar 2; 或其药学上可接受的盐。 Ar 1和Ar 2独立地为与任选取代的单环芳基稠合的取代或未取代的芳基或任选取代的五元或六元非芳族杂环基。 W和Y独立地为共价键或C 1 -C 3取代或未取代的亚烷基。 X是含有杂原子的官能团，芳香族杂环基，取代的芳香族杂环基，非芳香族杂环基，取代的非芳香族杂环基，烯烃基或取代烯烃基。 还公开了治疗患有高磷酸盐血症相关疾病的受试者以及由磷酸盐转运功能介导的疾病的方法。 该方法包括施用有效量的上述化合物之一的步骤。